Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
NEW YORK, Aug. 02, 2017 -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors who purchased IntelliPharmaCeutics International, Inc. (“IntelliPharmaCeutics” or the “Company”) (NASDAQ:IPCI) common stock between January 14, 2016 and July 26, 2017, inclusive (“Class Period”).
Investors who have incurred losses in IntelliPharmaCeutics International, Inc. are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.
If you have purchased securities of IntelliPharmaCeutics International, Inc., you may, no later than September 29, 2017, request that the Court appoint you lead plaintiff of the proposed class.
The filed Complaint alleges that during the Class Period, IntelliPharmaCeutics made false and/or misleading statements, and/or failed to disclose material information about its business and prospects.
On July 24, 2017, scientists from the U.S. Food & Drug Administration (“FDA”) expressed concerns that the Company failed to provide sufficient data about the abuse potential of its opioid painkilling drug, Rexista.
Subsequently, on July 26, 2017, IntelliPharmaCeutics announced that two advisory committees of the FDA voted 22 to 1 to oppose the Company’s New Drug Application (NDA) for Rexista, citing insufficient data regarding the abuse-deterrent properties of the drug as a motivating concern.
Following this news, the Company’s stock price closed at $1.36 per share, a decline of 45.4% from the previous close of $2.49 per share.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.
## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.
Contact: Wolf Haldenstein Adler Freeman & Herz LLP Kevin Cooper, Esq. Gregory Stone, Director of Case and Financial Analysis Email: [email protected], [email protected] or [email protected] Tel: (800) 575-0735 or (212) 545-4774
